![](/images/graphics-bg.png)
Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α : A Possible Mechanism for Modulation of Atherogenesis
المؤلفون المشاركون
Belilos, Elise
Seshadri, Sangeetha
Carsons, Steven E.
Voloshyna, Iryna
Anwar, Kamran
Reiss, Allison B.
Littlefield, Michael J.
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-01-23
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Tumor necrosis factor- (TNF-) α is a proinflammatory proatherogenic cytokine.
Infliximab, an anti-TNF-α monoclonal antibody, is effective in treating rheumatoid arthritis.
However, its impact on cardiovascular burden and lipid transport is unclear.
The present study investigates the effect of TNF-α and infliximab on reverse cholesterol transport (RCT) proteins.
Uptake of modified lipoproteins by macrophages in the vasculature leads to atherogenic foam cell formation.
RCT is mediated by proteins including ATP binding cassette transporters A1 (ABCA1), G1 (ABCG1), liver X receptor- (LXR-) α, and 27-hydroxylase.
RCT counteracts lipid overload by ridding cells of excess cholesterol.
THP-1 human monocytes were incubated with either TNF-α alone or TNF-α with infliximab.
Expression of proteins involved in cholesterol efflux was analyzed.
TNF-α significantly reduced both ABCA1 and LXR-α mRNA (to 68.5±1.59%, P<0.05, and 41.2±0.25%, P<0.01, versus control set as 100%, resp.).
Infliximab nullified the TNF-α effect.
Results were confirmed by Western blot.
Infliximab abolished the increase in foam cells induced by TNF-α.
TNF-α treatment significantly reduces ABCA1 and LXR-α expression in monocytes, thus bringing about a proatherogenic state.
The anti-TNF drug infliximab, commonly used in rheumatology, restored RCT proteins.
This is the first report of an atheroprotective effect of infliximab on RCT in monocytes.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Voloshyna, Iryna& Seshadri, Sangeetha& Anwar, Kamran& Littlefield, Michael J.& Belilos, Elise& Carsons, Steven E.…[et al.]. 2014. Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α : A Possible Mechanism for Modulation of Atherogenesis. BioMed Research International،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-462579
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Voloshyna, Iryna…[et al.]. Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α : A Possible Mechanism for Modulation of Atherogenesis. BioMed Research International No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-462579
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Voloshyna, Iryna& Seshadri, Sangeetha& Anwar, Kamran& Littlefield, Michael J.& Belilos, Elise& Carsons, Steven E.…[et al.]. Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α : A Possible Mechanism for Modulation of Atherogenesis. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-462579
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-462579
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)